Dr Agarwals Eye Hospital cash flow

Latest FY25
Cash from operations
₹94.5cr+5.2% on FY24
Free cash flow
₹94.5cr+5.2% on FY24
Cash from financing
₹16.6cr−₹14.2 cr in FY24
Cash from investing
−₹133cr−₹70.0 cr in FY24
₹ crore except per share
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—39.526.620.2
——7.0—
—−0.8−2.0—
Changes in working capital
—−3.7−3.8−0.3
—−1.5−3.7−2.0
—−0.16.9—
Cash from operating activities
93.670.762.349.4
—11510381.1
—20.113.611.5
—94.589.869.6
Cash from investing activities
—0.41.00.1
—11.8——
—0.10.90.2
—−133−70.0−70.6
Cash from financing activities
—56.215.0—
—11.17.5—
—22.918.98.4
—2.42.61.4
—16.6−14.20.3
—−21.75.5−0.7
—11.232.927.4
Reference items
14511991.174.7
30.9%29.8%28.5%27.9%
—94.589.869.6
—₹198.15₹188.27₹146.01
—1.73×1.94×1.89×
—20.113.611.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

DRAGARWQ₹5,299.50

Dr Agarwals Eye Hospital Limited

· Pharma & Health
₹ CrorePeersKMCSHILKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDMcap ₹2,527 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation20.226.639.5—
+ Finance Costs—7.0——
+ Interest Income—-2.0-0.8—
Changes in Working Capital
+ Inventories-0.3-3.8-3.7—
+ Trade Receivables — Current-2.0-3.7-1.5—
+ Trade Payables — Current—6.9-0.1—
Cash from Operating Activities
Profit Before Tax (per I/S)49.462.370.793.6
Cash from Operations (pre-tax)81.1103.4114.6—
+ Income Taxes Paid11.513.620.1—
Cash from Operating Activities69.689.894.5—
Cash from Investing Activities
+ Disp of Fixed Assets0.11.00.4—
+ Purchase of Investments (Equity / Debt)——11.8—
+ Interest Received — Investing0.20.90.1—
Cash from Investing Activities-70.6-70.0-132.8—
Cash from Financing Activities
+ Proceeds from Borrowings—15.056.2—
+ Repayment of Borrowings—7.511.1—
+ Payment of Lease Liabilities8.418.922.9—
+ Dividends Paid1.42.62.4—
Cash from Financing Activities0.3-14.216.6—
Net Changes in Cash-0.75.5-21.7—
Closing Cash27.432.911.2—
Reference Items
EBITDA74.791.1118.5145.3
EBITDA Margin %27.8828.5229.8430.86
Free Cash Flow (CFO − Capex)69.689.894.5—
Free Cash Flow per Basic Share146.01188.27198.15—
Cash Flow to Net Income1.891.941.73—
Cash Paid for Taxes11.513.620.1—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.